Inmode (INMD) Aandeel Koers
Inmode Koers
In de afgelopen 9 jaar liet Inmode de omzet jaarlijks met 36,1% groeien tot 370,50 Miljoen USD. De winst per aandeel is de afgelopen 9 jaar met 83,2% per jaar gegroeid. Bij Inmode is de nettowinstmarge met 25,3% ten opzichte van 46,1% enkele jaren geleden gedaald. Het consensus-koersdoel voor Inmode op 12 maanden bedraagt 19,00 USD, circa 34,4% boven de huidige koers. Van de 12 analisten geven 6 het aandeel een koopadvies — per saldo een Kopen-consensus.
Inmode aandeelkoers
Inmode bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Inmode
The business model of Inmode Ltd revolves around providing innovative medical aesthetics solutions. Inmode Ltd develops and markets advanced, minimally-invasive technologies used in aesthetic and surgical procedures. Their cutting-edge platforms, such as BodyTite, FaceTite, and Morpheus8, offer solutions for skin tightening, body contouring, facial rejuvenation, and cellulite reduction. Inmode Ltd's business model centers on combining radiofrequency technology with other modalities to deliver safe, efficient, and customizable treatments for both medical professionals and patients. By continuously developing and enhancing their product portfolio, they aim to meet the growing demands of the global aesthetic market and cater to the evolving needs of healthcare practitioners.
Inmode Ltd is primarily active in the aesthetic medical device industry.
The main competitors of Inmode Ltd in the market include companies such as Cutera Inc., Cynosure Inc., Alma Lasers Ltd., and Lumenis Ltd. These companies offer similar products and services in the medical aesthetics industry, which Inmode operates in. With its innovative technologies and strong market presence, Inmode competes with these industry players to gain a larger market share and maintain its position as a leading provider of aesthetic solutions.
Inmode Ltd is a leading global provider of innovative energy-based medical aesthetic solutions. Established in 2008, the company has rapidly grown to become a trusted name in the industry. Inmode's cutting-edge technology focuses on radiofrequency-based devices, enabling physicians to deliver effective aesthetic treatments with precision and optimal patient satisfaction. Inmode Ltd is headquartered in Israel but operates worldwide, serving thousands of medical professionals and patients alike. With a commitment to continuously expanding its portfolio and investing in research and development, Inmode Ltd remains at the forefront of the medical aesthetics field, dedicated to enhancing the lives of individuals through advanced and safe technology.
Inmode Ltd, a leading provider of medical aesthetic systems, has achieved several significant milestones. The company has successfully pioneered advanced technology in minimally invasive and non-invasive procedures for aesthetic treatments. Inmode Ltd has gained worldwide recognition for its innovative platform, which includes advanced radiofrequency, laser, and pulsed light technologies. With a strong focus on research and development, they have introduced cutting-edge solutions that address a wide range of aesthetic concerns effectively and safely. Inmode Ltd continues to revolutionize the field of medical aesthetics, solidifying its position as a market leader and providing patients with exceptional treatment options.
Inmode Ltd is primarily present in various countries and regions worldwide. The company's presence extends to the United States, where it has a significant market presence. In addition, Inmode Ltd has established a strong presence in Europe, including key markets such as Germany, France, Italy, and the United Kingdom. The company also operates in the Asia-Pacific region, with a focus on countries like China and Japan. With its global reach, Inmode Ltd continues to expand its presence and deliver innovative solutions in the field of aesthetic medical technology.
Inmode Ltd represents a strong set of core values and a corporate philosophy that distinguishes the company. With a focus on innovation and cutting-edge technology, Inmode aims to provide transformative solutions in the aesthetic and medical markets. The company prides itself on quality, reliability, and versatility, ensuring that customers can trust their products and services. Inmode's commitment to research and development enables them to deliver advanced solutions, empowering healthcare professionals to enhance patient care and achieve optimal results. By prioritizing customer satisfaction and continuous improvement, Inmode Ltd strives to remain a leader in the industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 19,00 USD voor het aandeel Inmode (mediaan: 19,00 USD), oftewel +34,4 % ten opzichte van de laatste koers. De consensus is gebaseerd op 12 analistenratings.
12 analisten beoordelen het aandeel Inmode momenteel: 6 adviseren kopen, 6 houden en 0 verkopen. Voor 2026 verwachten analisten dat Inmode een omzet van 370,32 Miljoen USD en winst per aandeel van 1,28 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Inmode op 12,61 EUR (14,14 USD).
Het aandeel Inmode (INMD) is genoteerd aan 4 beurzen, waaronder: NASDAQ (INMD), Frankfurt (154.F), München (154.MU), Düsseldorf (154.DU).
Inmode Ltd is a leading company in the medical technology industry, specializing in the development and commercialization of innovative aesthetic solutions. The company offers a wide range of products and services aimed at providing patients with fast, safe, and effective treatment for aesthetic problems. Inmode specializes in four main areas: body contouring and fat reduction, skin tightening, wrinkle reduction and skin rejuvenation, and common skin problems. To address these areas, the company has developed various advanced technologies and devices available to doctors and clinics. These include: - BodyTite: A revolutionary technology that uses radiofrequency energy to melt tissue, leading to effective body contouring with minimal invasiveness. - FaceTite: A technology based on the same principles as BodyTite but specifically developed for the face and neck to tighten loose skin and reduce wrinkles. - Morpheus8: A combination of micro-needles and radiofrequency energy that stimulates collagen production and tightens the skin, reducing wrinkles and unevenness. - Votiva: A device specifically designed for women that tightens the vagina and improves sexual health. These areas and products aim to cover the entire spectrum of aesthetic needs in order to build a successful and growing customer base. Inmode also has a unique business model that goes beyond traditional sales efforts. The company has developed a strong online presence that provides potential customers with everything they need to know about the company's products and services. Inmode has also built close relationships with medical professionals around the world to ensure that their products and technologies meet the highest medical standards. In addition to providing advanced medical devices to doctors and clinics, Inmode has also developed comprehensive training and support programs to ensure that doctors and clinics are trained in the use of their technologies and can achieve the best possible results for their patients. This business model has contributed to the company's growth and success in recent years, becoming a key factor in the aesthetic medicine industry. Overall, Inmode's business model demonstrates how innovative technologies and high-quality products and services, combined with online marketing and customer relationships, can lead to a successful company.
De verwachte omzet van Inmode bedraagt 370,32 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Inmode bedraagt 82,11 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Inmode bedraagt momenteel 11,03. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Inmode-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Inmode bedraagt momenteel 2,45. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Inmode-aandeel.
De Eulerpool Kwaliteitsscore voor Inmode is 3/10.
De ISIN van Inmode is IL0011595993. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Inmode is A2PP3A. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Inmode is INMD. Onder dit beurstickersymbool wordt het Inmode-aandeel op de beurs verhandeld.
Inmode aandeel
Inmode Ticker
Inmode FIGI
Alle fundamentals en diepgaande analyse van Inmode
Onze aandelenanalyse van het Inmode-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Inmode. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: